{
    "clinical_study": {
        "@rank": "124380", 
        "arm_group": [
            {
                "arm_group_label": "Intranasal (IN) naloxone", 
                "arm_group_type": "Experimental", 
                "description": "Intranasal (IN) naloxone as initial response to suspected opioid overdose"
            }, 
            {
                "arm_group_label": "Standard of Care (TAU)", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard of care (intravenous [IV], intramuscular [IM] or intraosseus [IO]delivery of naloxone) as initial response to suspected opioid overdose."
            }
        ], 
        "brief_summary": {
            "textblock": "The goal of this study is to determine if nasal naloxone is inferior to standard care for\n      naloxone administration in a pre-hospital setting. Ambulance squads in Adams, Clermont, and\n      Scioto counties in southern Ohio will be randomized to provide either standard care or nasal\n      (IN) naloxone as the initial response to a suspected opioid overdose. Standard care includes\n      administration of naloxone by intravenous (IV), intramuscular (IM) or intraosseus (IO)\n      methods."
        }, 
        "brief_title": "Nasal Naloxone for Narcotic Overdose", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Drug Overdose", 
        "condition_browse": {
            "mesh_term": "Overdose"
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, prospective trial that will compare clinical outcomes for parenteral\n      naloxone according to the standard of care (TAU; administration via intravenous [IV],\n      intramuscular [IM] or intraosseus [IO] delivery) versus intranasal [IN] for the prehospital\n      emergency treatment of suspected opioid overdose. Ambulance squads in Adams, Clermont, and\n      Scioto counties in southern Ohio will be randomized to administer either standard care or IN\n      naloxone as the initial response to a suspected opioid overdose."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Presence of hyperventilation or respiratory arrest OR\n\n          -  EMS assessment that the person needs naloxone for possible opioid or unknown drug\n             overdose\n\n        Exclusion Criteria:\n\n          -  EMS assessment that the participant is less than 12 years old"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "236", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01912573", 
            "org_study_id": "N3OD", 
            "secondary_id": "Ohio Division of EMS Board"
        }, 
        "intervention": [
            {
                "arm_group_label": "Intranasal (IN) naloxone", 
                "intervention_name": "Intranasal (IN) naloxone", 
                "intervention_type": "Drug", 
                "other_name": "Narcan"
            }, 
            {
                "arm_group_label": "Standard of Care (TAU)", 
                "intervention_name": "Intravenous (IV) naloxone", 
                "intervention_type": "Drug", 
                "other_name": "Narcan"
            }, 
            {
                "arm_group_label": "Standard of Care (TAU)", 
                "intervention_name": "Intramuscular (IM) naloxone", 
                "intervention_type": "Drug", 
                "other_name": "Narcan"
            }, 
            {
                "arm_group_label": "Standard of Care (TAU)", 
                "intervention_name": "Intraosseus (IO) naloxone", 
                "intervention_type": "Drug", 
                "other_name": "Narcan"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Naloxone", 
                "Narcotics"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "heroin", 
            "prescription pain killers", 
            "narcotics"
        ], 
        "lastchanged_date": "July 29, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Joe Renusch, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Batavia", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Clermont County"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Brian Barhorst, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Portsmouth", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Scioto County"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Bruce Ashley, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "West Union", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Adams County"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Nasal Naloxone for Narcotic Overdose", 
        "overall_official": {
            "affiliation": "University of Cincinnati", 
            "last_name": "Judith Feinberg, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of patients with adequate respiration within 10 minutes", 
            "safety_issue": "Yes", 
            "time_frame": "10 minutes after intervention administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01912573"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Cincinnati", 
            "investigator_full_name": "Judith Feinberg", 
            "investigator_title": "Assoc Chair of Medicine", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of patients requiring second dose of naloxone", 
                "safety_issue": "Yes", 
                "time_frame": "within 10 minutes of initial dose"
            }, 
            {
                "description": "Time between emergency call and administration of naloxone.", 
                "measure": "Time to first naloxone administration", 
                "safety_issue": "No", 
                "time_frame": "at baseline"
            }, 
            {
                "measure": "Opioid Withdrawal Symptoms", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "measure": "Naloxone Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "3 hours"
            }, 
            {
                "measure": "Proportion of Patients breathing unassisted upon arrival to the hospital", 
                "safety_issue": "No", 
                "time_frame": "within 1 hour"
            }, 
            {
                "measure": "Days of hospitalization following naloxone administration", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Mortality rate", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }
        ], 
        "source": "University of Cincinnati", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Judith Feinberg", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}